Apimeds Pharmaceuticals US, Inc., a clinical-stage biotechnology company in Matawan, announced that it has merged with MindWave Innovations Inc.
The merger combines Apimeds’ late-stage, non-opioid pain-management biologic portfolio with MindWave’s AI-driven Bitcoin treasury, digital asset yield generation and $NILA-powered ecosystem.
The combined company integrates high-growth biotechnology and institutional digital treasury capabilities, with the merger supported by a simultaneous PIPE of up to $100 million to advance Apimeds’ clinical programs and expand MindWave’s digital asset infrastructure.
“As Apimeds moves toward its Phase 3 clinical trial initiation, we continue to focus on financing and expansion,” Said Erik Emerson, CEO of Apimeds. “When I met the leadership team at MindWave and saw the strength and scalability of their business, it became clear this merger represented a unique opportunity.
“Biotech requires significant capital, and integrating a high-yield digital asset business with strong cash-flow potential will allow us to accelerate our therapeutic programs.”
“The NYSE American listing, combined with our three-pronged approach to Bitcoin treasury infrastructure, refined AI-supported yield capabilities and a scalable multi-vertical ecosystem powered by the $NILA token, positions MindWave at the forefront of institutional digital treasury management,” said Dr. Vin Menon, founder and CEO of MindWave.
“Joining forces with Apimeds creates a diversified organization designed to drive long-term value and maximize stockholder returns.”
MindWave’s three-pronged strategic framework includes secure digital treasury wallets for corporations; AI-enhanced Bitcoin yield generation; and a validator-powered ecosystem supported by the $NILA Token. Together, these capabilities make MindWave one of the first companies to pursue a publicly traded, institutional-focused digital asset treasury (DAT) model.
Apimeds focuses on developing non-opioid, biologic-based therapies for pain management. Its lead product candidate, Apitox, is in late-stage clinical development for the treatment of knee osteoarthritis.
